Target Healthc. Regulatory News (THRL)

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, TO THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA, JAPAN OR ANY MEMBER STATE OF THE EEA (OTHER THAN THE UNITED KINGDOM) OR TO ANY NATIONAL, RESIDENT OR CITIZEN OF THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA, JAPAN OR ANY MEMBER STATE OF THE EEA (OTHER THAN THE UNITED KINGDOM)

This announcement is an advertisement and does not constitute a prospectus and investors must only subscribe for or purchase any shares referred to in this announcement on the basis of information contained in the prospectus issued by Target Healthcare REIT Limited on 5 September 2014, as supplemented on 7 January 2015, 20 February 2015 and 24 February 2015 (the "Prospectus") and not in reliance on this announcement. Copies of the Prospectus may, subject to any applicable law, be obtained from the registered office of the Company. This announcement does not constitute and may not be construed as, an offer to sell or an invitation to purchase, investments of any description, a recommendation regarding the issue or the provision of investment advice by any party. No information set out in this announcement or referred to in other written or oral form is intended to form the basis of any contract of sale, investment decision or any decision to purchase shares in the Company.

TARGET HEALTHCARE REIT LIMITED

("Target" or the "Company")

RESULTS OF PLACING

Further to the announcement dated 11 February 2015, the Board of Target is pleased to announce the successful placing of 25,000,000 new ordinary shares ("New Shares") pursuant to the terms and conditions of the Placing Programme established under the Prospectus. The New Shares have been placed, subject to Admission, by Stifel Nicolaus Europe Limited at a price per New Share of 102.00 pence and the Company has therefore raised gross proceeds of approximately £25.5 million.

The New Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with the existing ordinary shares.

Application has been made for the New Shares to be admitted to the premium segment of the Official List of the Financial Conduct Authority (the "FCA") and to trading on the main market for listed securities of the London Stock Exchange ("Admission"). It is expected that Admission will become effective and unconditional dealings in the New Shares will commence at 8.00 a.m. on 6 March 2015.

Following Admission, the number of ordinary shares that the Company has in issue will be 142,298,226. The total number of voting rights of the Company will be 142,298,226 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company, under the Disclosure and Transparency Rules.

The New Shares will be issued in registered form and may be held in uncertificated form. The New Shares allocated will be issued to Placees through the CREST system unless otherwise stated. The New Shares will be eligible for settlement through CREST with effect from Admission.

Commenting, Malcolm Naish, Non-Executive Chairman of Target said:

"This placing was oversubscribed and we are encouraged by the support shown by the current shareholders in Target. We are also delighted that we have been able to attract new investors hearing the investment story for the first time. We have already identified attractive acquisition opportunities and look forward to being able to report more fully in due course".

FOR FURTHER INFORMATION, PLEASE CONTACT:

Important Information

The content of this announcement is the sole responsibility of Target Healthcare REIT Limited.

This announcement is an advertisement and does not constitute a prospectus and investors must only subscribe for or purchase any shares referred to in this announcement on the basis of information contained in the Prospectus published by Target Healthcare REIT Limited as supplemented and not in reliance on this announcement. Copies of the Prospectus may, subject to any applicable law, be obtained from the registered offices of the Company at Ordnance House, 31 Pier Road, St. Helier, Jersey JE4 8PW. This announcement does not constitute and may not be construed as, an offer to sell or an invitation to purchase, investments of any description, a recommendation regarding the issue or the provision of investment advice by any party. No information set out in this announcement or referred to in other written or oral form is intended to form the basis of any contract of sale, investment decision or any decision to purchase shares in the Company.

The information contained in this announcement is given at the date of its publication (unless otherwise marked) and is subject to updating, revision and amendment from time to time.

Stifel Nicolaus Europe Limited, which is authorised and regulated by the Financial Conduct Authority, is acting only for the Company in connection with the matters described in this announcement and is not acting for or advising any other person, or treating any other person as its client, in relation thereto and will not be responsible for providing the regulatory protection afforded to clients of Stifel Nicolaus Europe Limited or advice to any other person in relation to the matters contained herein.

None of the Company, Target Advisers LLP or Stifel Nicolaus Europe Limited, or any of their respective affiliates, accepts any responsibility or liability whatsoever for or makes any representation or warranty, express or implied, as to this announcement, including the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of the announcement or its contents or otherwise arising in connection therewith. The Company, Target Advisers LLP and Stifel Nicolaus Europe Limited, and their respective affiliates, accordingly disclaim all and any liability whether arising in tort, contract or otherwise which they might otherwise have in respect of this announcement or its contents or otherwise arising in connection therewith.